What is Alexion known for?
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma.
What happened to Alexion Pharmaceuticals?
AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
When was Alexion founded?
1992, New Haven, Connecticut, United States
Alexion Pharmaceuticals/Founded
Who founded Alexion Pharmaceuticals?
Leonard Bell
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide….Alexion Pharmaceuticals.
| Type | Subsidiary |
|---|---|
| Traded as | Nasdaq: ALXN |
| Industry | Pharmaceutical industry |
| Founded | 1992 |
| Founder | Leonard Bell |
Who are Alexion competitors?
Alexion Pharmaceuticals’s top competitors include Regeneron Pharmaceuticals, Amanta Healthcare, Deciphera Pharmaceuticals and Heron Therapeutics. Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.
What did AstraZeneca pay for Alexion?
$39 billion
New Jersey-based Caelum will become part of AstraZeneca’s Alexion division, the rare diseases specialist it bought for $39 billion earlier this year.
When did AstraZeneca acquire Alexion?
Dive Brief: AstraZeneca expects to complete its $39 billion acquisition of Alexion on July 21 after receiving the last regulatory clearance it needed, from the U.K. Competition and Markets Authority.
Who started Alexion?
Who bought Alexion?
AstraZeneca’s
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review. Cambridge-based AstraZeneca (AZ) first announced its intention to buy out Alexion in December.
How many employees does Alexion Pharmaceuticals have?
2,500 employees
Alexion has approximately 2,500 employees around the globe and serves patients in more than 50 countries. There are limitless opportunities for talented individuals to work across functions and geographies, taking on new challenges and building the future of the company. Learn more about our global opportunities.
Who are the founders of Alexion pharmaceutical company?
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Bell served as the company’s CEO until 2015. In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut.
What makes Alexion a great place to work?
Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do.
Why is Alexion important to people with rare diseases?
At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day. I don’t define myself as having a rare disease.
When did Alexion Pharmaceuticals move to Cheshire CT?
In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion received U.S. Food and Drug Administration ( FDA) approval for Soliris in 2007.